TW202114694A - 四環化合物及其鹽類、組合物、及彼等之使用方法 - Google Patents

四環化合物及其鹽類、組合物、及彼等之使用方法 Download PDF

Info

Publication number
TW202114694A
TW202114694A TW109127804A TW109127804A TW202114694A TW 202114694 A TW202114694 A TW 202114694A TW 109127804 A TW109127804 A TW 109127804A TW 109127804 A TW109127804 A TW 109127804A TW 202114694 A TW202114694 A TW 202114694A
Authority
TW
Taiwan
Prior art keywords
compound
cancer
pharmaceutically acceptable
individual
acceptable salt
Prior art date
Application number
TW109127804A
Other languages
English (en)
Chinese (zh)
Inventor
佳恩 宋
Original Assignee
生華生物科技股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 生華生物科技股份有限公司 filed Critical 生華生物科技股份有限公司
Publication of TW202114694A publication Critical patent/TW202114694A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TW109127804A 2019-08-14 2020-08-14 四環化合物及其鹽類、組合物、及彼等之使用方法 TW202114694A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962886621P 2019-08-14 2019-08-14
US62/886,621 2019-08-14
US201962946774P 2019-12-11 2019-12-11
US62/946,774 2019-12-11

Publications (1)

Publication Number Publication Date
TW202114694A true TW202114694A (zh) 2021-04-16

Family

ID=74568302

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109127804A TW202114694A (zh) 2019-08-14 2020-08-14 四環化合物及其鹽類、組合物、及彼等之使用方法

Country Status (12)

Country Link
US (1) US20210046071A1 (OSRAM)
EP (1) EP4013421A4 (OSRAM)
JP (1) JP7566010B2 (OSRAM)
KR (1) KR20220130085A (OSRAM)
CN (1) CN114599368A (OSRAM)
AU (1) AU2020328590B2 (OSRAM)
BR (1) BR112022002784A2 (OSRAM)
CA (1) CA3151112A1 (OSRAM)
IL (1) IL290626A (OSRAM)
PH (1) PH12022550360A1 (OSRAM)
TW (1) TW202114694A (OSRAM)
WO (1) WO2021030671A1 (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3005730A1 (en) 2015-11-20 2017-05-26 Senhwa Biosciences, Inc. Combination therapy of tetracyclic quinolone analogs for treating cancer
TWI884912B (zh) 2018-02-15 2025-06-01 生華生物科技股份有限公司 喹啉酮類似物及其鹽、組合物及其使用方法
CN114409681A (zh) * 2022-03-18 2022-04-29 信义核新(北京)生物科技有限公司 用于治疗dna损伤修复缺陷肿瘤的喹诺酮类似物及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101888780B (zh) 2007-10-05 2014-08-13 生华生物科技股份有限公司 喹诺酮类似物及其相关方法
WO2011063398A1 (en) * 2009-11-23 2011-05-26 Cylene Pharamaceuticals, Inc. Polymorphs and salts of a kinase inhibitor
WO2015079411A1 (en) * 2013-11-28 2015-06-04 Tel Hashomer Medical Research Infrastructure And Services Ltd. Rna polymerase i inhibitors and uses thereof
CA3005730A1 (en) * 2015-11-20 2017-05-26 Senhwa Biosciences, Inc. Combination therapy of tetracyclic quinolone analogs for treating cancer
US9957282B2 (en) * 2015-12-14 2018-05-01 Senhwa Biosciences, Inc. Crystalline forms of quinolone analogs and their salts
WO2017105382A1 (en) * 2015-12-14 2017-06-22 Ryckman David M Crystalline forms of quinolone analogs and their salts
TWI884912B (zh) * 2018-02-15 2025-06-01 生華生物科技股份有限公司 喹啉酮類似物及其鹽、組合物及其使用方法

Also Published As

Publication number Publication date
AU2020328590A1 (en) 2022-03-10
US20210046071A1 (en) 2021-02-18
JP2022544559A (ja) 2022-10-19
BR112022002784A2 (pt) 2022-08-09
CN114599368A (zh) 2022-06-07
CA3151112A1 (en) 2021-02-18
EP4013421A1 (en) 2022-06-22
KR20220130085A (ko) 2022-09-26
EP4013421A4 (en) 2023-08-23
PH12022550360A1 (en) 2023-02-27
WO2021030671A1 (en) 2021-02-18
AU2020328590B2 (en) 2026-03-26
IL290626A (en) 2022-04-01
JP7566010B2 (ja) 2024-10-11

Similar Documents

Publication Publication Date Title
TWI730013B (zh) 用於治療癌症的四環喹諾酮類似物組合療法
US11524012B1 (en) Quinolone analogs and their salts, compositions, and method for their use
AU2018285823A1 (en) Tinostamustine for use in treating ovarian cancer
AU2020328590B2 (en) Tetracyclic compounds and their salts, compositions, and methods for their use
CA2944255C (en) New derivatives of cephalosporin for treating cancer
EP3852744B1 (en) Combination therapy for the treatment of uveal melanoma
WO2021154976A1 (en) Methods of treating brain cancer with panobinostat
US20220062294A1 (en) Pharmaceutical compositions of tetracyclic quinolone analogs and their salts
TW202115091A (zh) 喹啉類似物之結晶型及其鹽類、組合物、及彼等之使用方法
US20080207644A1 (en) Therapeutic materials and methods
EP3967310B1 (en) Quinoline derivative and epirubicin used for soft tissue sarcoma combination therapy
US20230038138A1 (en) Combination therapy for treating cancer
TW200922595A (en) Organic compounds
TW202339726A (zh) 用於治療癌症之與畢尼替尼(Binimetinib)併用之HDAC抑制劑OKI-179
TW202327579A (zh) Ｔｅａｄ抑制劑的給藥方案
CN112294813A (zh) 喹啉衍生物在治疗脊索瘤中的用途
CN103221050A (zh) 用于治疗增生性障碍的贝伐单抗与2,2-二甲基-N-((S)-6-氧代-6,7-二氢-5H-二苯并[b,d]氮杂*-7-基)-N`-(2,2,3,3,3-五氟-丙基)-丙二酰胺的组合
WO2026107242A1 (en) Ras and pd-1 or pd-l1 inhibitors combination therapy
JP2024542831A (ja) Ｐｋｃ阻害剤及びｃ－ｍｅｔ阻害剤を含む併用療法
KR20100058662A (ko) 개에게서 림프종을 치료하기 위한 이다루비신
HK40067323B (en) Quinoline derivative and epirubicin used for soft tissue sarcoma combination therapy
HK1233924A1 (en) Derivatives of cephalosporin for treating cancer
HK1233924B (en) Derivatives of cephalosporin for treating cancer